NeoGenomics to Present New Research at AACR Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy NEO?
Source: Newsfilter
- Research Presentation: NeoGenomics will showcase eight scientific posters and one oral presentation at the 2026 AACR Annual Meeting, emphasizing its capabilities in integrating clinical and genomic insights through its Oncology Data Solutions platform, which is expected to advance precision medicine.
- Clinical Data Integration: By linking laboratory testing with clinical data, NeoGenomics has demonstrated its ability to drive deeper characterization of biomarker prevalence and evaluation of testing concordance, thereby providing critical clinical insights for oncology therapy development.
- Partnership Collaborations: The company's collaborations with biopharma partners have enabled the development of compelling research, with CEO Tony Zook stating that these findings will directly enhance therapy development and create more options for providers and patients.
- Future Outlook: NeoGenomics' research not only showcases its leadership in the oncology field but also has the potential to promote the development and commercialization of novel oncology therapies by facilitating translational research into clinical applications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEO
Wall Street analysts forecast NEO stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 8.350
Low
12.00
Averages
14.00
High
16.00
Current: 8.350
Low
12.00
Averages
14.00
High
16.00
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeoGenomics to Present New Research at AACR Annual Meeting
- Research Presentation: NeoGenomics will showcase eight scientific posters and one oral presentation at the 2026 AACR Annual Meeting, emphasizing its capabilities in integrating clinical and genomic insights through its Oncology Data Solutions platform, which is expected to advance precision medicine.
- Clinical Data Integration: By linking laboratory testing with clinical data, NeoGenomics has demonstrated its ability to drive deeper characterization of biomarker prevalence and evaluation of testing concordance, thereby providing critical clinical insights for oncology therapy development.
- Partnership Collaborations: The company's collaborations with biopharma partners have enabled the development of compelling research, with CEO Tony Zook stating that these findings will directly enhance therapy development and create more options for providers and patients.
- Future Outlook: NeoGenomics' research not only showcases its leadership in the oncology field but also has the potential to promote the development and commercialization of novel oncology therapies by facilitating translational research into clinical applications.
See More
NeoGenomics to Report Q1 2026 Financial Results on April 28
- Earnings Release Schedule: NeoGenomics will report its Q1 2026 financial results after the U.S. market closes on April 28, reflecting the company's commitment to transparency and investor communication.
- Webcast and Conference Call: Management will host a live webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights, aiming to enhance investor understanding and confidence in the company's performance.
- New Quarterly Call Protocol: Starting with Q1 2026, NeoGenomics will hold quarterly earnings calls after market close, allowing for follow-up discussions before the next trading day, thereby improving information dissemination efficiency.
- Global Laboratory Network: NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the U.S. and the U.K., providing comprehensive cancer genetics testing and information services, further solidifying its leadership in precision medicine.
See More
U.S. Launches $12 Billion Strategic Minerals Reserve Initiative
- Project Launch: On February 2, 2026, the White House initiated Project Vault, a $12 billion strategic minerals reserve program aimed at covering all 60 minerals on the USGS Critical Minerals List, highlighting the government's commitment to securing mineral supply chains.
- International Cooperation: During the 2026 Critical Minerals Ministerial, Secretary of State Rubio confirmed over $30 billion in U.S. government support for secure supply chains, reflecting America's strategic positioning in the global mineral resource competition.
- Market Dynamics: The IEA projects a 30% copper shortfall by 2035, while rare earth supplies outside China meet less than 40% of projected demand, creating upward pressure on commodity prices, particularly as uranium approaches $92 per pound amid rising reactor demand.
- Corporate Positioning: EagleOne Metals recently acquired the Poison Springs uranium/rare earth project in Utah for $50,000, showcasing its diversified exposure in critical minerals, which is expected to enhance its market value and competitive edge.
See More
NeoGenomics Secures Medicare Coverage for PanTracer LBx Test
- Medicare Coverage Milestone: NeoGenomics' PanTracer LBx test has received coverage from Medicare, significantly enhancing accessibility to precision oncology in community settings, which is expected to lead to more patients receiving personalized treatment.
- Blood Test Advantages: The test provides actionable biomarker information from a simple blood draw, evaluating over 500 genes with a seven-day turnaround, meeting the flexible needs of both patients and clinicians, thereby promoting the adoption of advanced cancer diagnostics.
- Clinical Application Expansion: PanTracer LBx complements the PanTracer Tissue test, enabling comprehensive tumor profiling and reducing barriers for patients to access advanced cancer diagnostics, further solidifying NeoGenomics' market position in precision oncology.
- Market Potential: The Medicare coverage decision is anticipated to drive clinical adoption of PanTracer LBx, enhancing physicians' ability to deliver timely, personalized treatment strategies, thereby increasing the real-world utility of patient care.
See More
NeoGenomics Launches RaDaR ST for Molecular Residual Disease Detection
- Significant Market Potential: The MRD market is estimated to exceed $20 billion, growing at an annual rate of 30%, with less than 10% penetration, presenting substantial growth opportunities for NeoGenomics' RaDaR ST and potentially driving future revenue growth.
- Technological Innovation: RaDaR ST detects trace amounts of tumor DNA in blood using patient-specific tumor-informed panels, achieving a sensitivity of 95%, enabling early detection before recurrence is visible on imaging, thus aiding clinicians in making more informed treatment decisions.
- Broad Clinical Applications: The assay has been validated in various cancers, including breast and HPV-negative head and neck cancers, demonstrating effectiveness for long-term surveillance and early recurrence detection in high-risk populations, further solidifying NeoGenomics' leadership in oncology diagnostics.
- Comprehensive Solution: The launch of RaDaR ST allows NeoGenomics to offer a complete solid tumor care solution, enhancing the company's competitiveness across the entire cancer treatment continuum from comprehensive diagnostics to personalized MRD assessment.
See More
NeoGenomics Reports Record Q4 2025 Revenues of $190 Million
- Significant Revenue Growth: NeoGenomics reported Q4 2025 revenues of $190 million, an 11% year-over-year increase, with clinical business revenue rising 16%, demonstrating the company's strong market performance and effective execution of its commercial strategy.
- Strong NGS Performance: The company achieved a 23% growth in NGS revenue, significantly outpacing the market growth rate, indicating its leadership position and increased market share in high-value testing.
- Synergies from Pathline Acquisition: The acquisition of Pathline is expected to yield operational efficiencies and synergies, with profitability improvements anticipated to begin in 2026, further strengthening the company's lab network.
- Optimistic 2026 Outlook: NeoGenomics projects 2026 revenues between $793 million and $801 million, with adjusted EBITDA expected to grow by 27% to 31%, reflecting confidence in future growth driven by the launches of RaDaR ST and PanTracer products, which are expected to accelerate revenue growth.
See More
NeoGenomics to Present New Research at AACR Annual Meeting
- Research Presentation: NeoGenomics will showcase eight scientific posters and one oral presentation at the 2026 AACR Annual Meeting, emphasizing its capabilities in integrating clinical and genomic insights through its Oncology Data Solutions platform, which is expected to advance precision medicine.
- Clinical Data Integration: By linking laboratory testing with clinical data, NeoGenomics has demonstrated its ability to drive deeper characterization of biomarker prevalence and evaluation of testing concordance, thereby providing critical clinical insights for oncology therapy development.
- Partnership Collaborations: The company's collaborations with biopharma partners have enabled the development of compelling research, with CEO Tony Zook stating that these findings will directly enhance therapy development and create more options for providers and patients.
- Future Outlook: NeoGenomics' research not only showcases its leadership in the oncology field but also has the potential to promote the development and commercialization of novel oncology therapies by facilitating translational research into clinical applications.
See More
NeoGenomics to Report Q1 2026 Financial Results on April 28
- Earnings Release Schedule: NeoGenomics will report its Q1 2026 financial results after the U.S. market closes on April 28, reflecting the company's commitment to transparency and investor communication.
- Webcast and Conference Call: Management will host a live webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights, aiming to enhance investor understanding and confidence in the company's performance.
- New Quarterly Call Protocol: Starting with Q1 2026, NeoGenomics will hold quarterly earnings calls after market close, allowing for follow-up discussions before the next trading day, thereby improving information dissemination efficiency.
- Global Laboratory Network: NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the U.S. and the U.K., providing comprehensive cancer genetics testing and information services, further solidifying its leadership in precision medicine.
See More
U.S. Launches $12 Billion Strategic Minerals Reserve Initiative
- Project Launch: On February 2, 2026, the White House initiated Project Vault, a $12 billion strategic minerals reserve program aimed at covering all 60 minerals on the USGS Critical Minerals List, highlighting the government's commitment to securing mineral supply chains.
- International Cooperation: During the 2026 Critical Minerals Ministerial, Secretary of State Rubio confirmed over $30 billion in U.S. government support for secure supply chains, reflecting America's strategic positioning in the global mineral resource competition.
- Market Dynamics: The IEA projects a 30% copper shortfall by 2035, while rare earth supplies outside China meet less than 40% of projected demand, creating upward pressure on commodity prices, particularly as uranium approaches $92 per pound amid rising reactor demand.
- Corporate Positioning: EagleOne Metals recently acquired the Poison Springs uranium/rare earth project in Utah for $50,000, showcasing its diversified exposure in critical minerals, which is expected to enhance its market value and competitive edge.
See More
NeoGenomics Secures Medicare Coverage for PanTracer LBx Test
- Medicare Coverage Milestone: NeoGenomics' PanTracer LBx test has received coverage from Medicare, significantly enhancing accessibility to precision oncology in community settings, which is expected to lead to more patients receiving personalized treatment.
- Blood Test Advantages: The test provides actionable biomarker information from a simple blood draw, evaluating over 500 genes with a seven-day turnaround, meeting the flexible needs of both patients and clinicians, thereby promoting the adoption of advanced cancer diagnostics.
- Clinical Application Expansion: PanTracer LBx complements the PanTracer Tissue test, enabling comprehensive tumor profiling and reducing barriers for patients to access advanced cancer diagnostics, further solidifying NeoGenomics' market position in precision oncology.
- Market Potential: The Medicare coverage decision is anticipated to drive clinical adoption of PanTracer LBx, enhancing physicians' ability to deliver timely, personalized treatment strategies, thereby increasing the real-world utility of patient care.
See More
NeoGenomics Launches RaDaR ST for Molecular Residual Disease Detection
- Significant Market Potential: The MRD market is estimated to exceed $20 billion, growing at an annual rate of 30%, with less than 10% penetration, presenting substantial growth opportunities for NeoGenomics' RaDaR ST and potentially driving future revenue growth.
- Technological Innovation: RaDaR ST detects trace amounts of tumor DNA in blood using patient-specific tumor-informed panels, achieving a sensitivity of 95%, enabling early detection before recurrence is visible on imaging, thus aiding clinicians in making more informed treatment decisions.
- Broad Clinical Applications: The assay has been validated in various cancers, including breast and HPV-negative head and neck cancers, demonstrating effectiveness for long-term surveillance and early recurrence detection in high-risk populations, further solidifying NeoGenomics' leadership in oncology diagnostics.
- Comprehensive Solution: The launch of RaDaR ST allows NeoGenomics to offer a complete solid tumor care solution, enhancing the company's competitiveness across the entire cancer treatment continuum from comprehensive diagnostics to personalized MRD assessment.
See More
NeoGenomics Reports Record Q4 2025 Revenues of $190 Million
- Significant Revenue Growth: NeoGenomics reported Q4 2025 revenues of $190 million, an 11% year-over-year increase, with clinical business revenue rising 16%, demonstrating the company's strong market performance and effective execution of its commercial strategy.
- Strong NGS Performance: The company achieved a 23% growth in NGS revenue, significantly outpacing the market growth rate, indicating its leadership position and increased market share in high-value testing.
- Synergies from Pathline Acquisition: The acquisition of Pathline is expected to yield operational efficiencies and synergies, with profitability improvements anticipated to begin in 2026, further strengthening the company's lab network.
- Optimistic 2026 Outlook: NeoGenomics projects 2026 revenues between $793 million and $801 million, with adjusted EBITDA expected to grow by 27% to 31%, reflecting confidence in future growth driven by the launches of RaDaR ST and PanTracer products, which are expected to accelerate revenue growth.
See More
